Mer­ck part­ner Arti­va blue­prints San Diego R&D, man­u­fac­tur­ing site to take NK cell op­er­a­tion to the next lev­el

In Jan­u­ary, Arti­va Bio­ther­a­peu­tics CEO Fred Aslan said his com­pa­ny is look­ing to cre­ate CAR-NK ther­a­pies with best-in-class ef­fi­ca­cy made in a whol­ly owned man­u­fac­tur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER